Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | 225Ac-J591 |
| Synonyms | |
| Therapy Description |
225Ac-J591 is a radioconjugate comprising the alpha-radiation emitting radionuclide actinium-225 linked to a monoclonal antibody that targets PSMA (J591), which delivers radiation to PSMA-expressing tumor cells, potentially resulting in antitumor activity (PMID: 37922438). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| 225Ac-J591 | Ac 225 MOAB J591|Ac-225 Anti-PSMA J591|Ac-225 rosopatamab tetraxetan | PSMA Antibody 20 | 225Ac-J591 is a radioconjugate comprising the alpha-radiation emitting radionuclide actinium-225 linked to a monoclonal antibody that targets PSMA (J591), which delivers radiation to PSMA-expressing tumor cells, potentially resulting in antitumor activity (PMID: 37922438). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05567770 | Phase I | 225Ac-J591 | ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer (ACTION) | Withdrawn | 0 | |
| NCT06549465 | Phase II | 225Ac-J591 | Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
| NCT04576871 | Phase I | 225Ac-J591 | Re-treatment 225Ac-J591 for mCRPC | Active, not recruiting | USA | 0 |
| NCT03276572 | Phase I | 225Ac-J591 | Phase I Trial of 225Ac-J591 in Patients With mCRPC | Completed | USA | 0 |
| NCT04506567 | Phase Ib/II | 225Ac-J591 | Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC | Suspended | USA | 0 |
CKB BOOST